Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Respiratory Depression After the Second Dose of Intravenous Tramadol in a Rectal Cancer Patient with Normal Renal Function: A Clinical Case Report

정상 신기능 직장암 환자에서 Intravenous Tramadol 이회 투여 후 호흡곤란 발생 증례 보고

  • Kang, Hee-Won (Department of Pharmacy, Sevrance Hospital, Yonsei University) ;
  • Lee, Yu-Jeung (Graduate School of Clinical Pharmacy, Sookmyung Women's University)
  • 강희원 (연세대학교 세브란스병원 약무국) ;
  • 이유정 (숙명여자대학교 임상약학대학원)
  • Received : 2010.12.21
  • Accepted : 2011.03.04
  • Published : 2011.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

We report an unusual case of respiratory depression and prolonged apnea after the second dose of 100-mg intravenous tramadol. Due to continuous pain at foley catheter keep site, intravenous tramadol was administered to the patient. Soon after the second dose of tramadol injection, the patient became apneic. The patient did not respond to verbal command and started exhibiting oxygen desaturation. The patient was quickly treated with 100% oxygen, and it took 4 hours for the spontaneous respiration to return to regular. This case report demonstrates that even two doses of tramadol administered intravenously may manifest as sudden and prolonged apnea. Respiratory depression with tramadol has been reported in patients with impaired renal functions and Cytochrome P(CYP) 2D6 gene duplication.

Keywords

References

  1. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004; 43: 879-923. https://doi.org/10.2165/00003088-200443130-00004
  2. American Society of Health-System Pharmacists. Tramadol hydrochloride, In: American Society of Health-System Pharmacists. AHFS Drug Information, 2010; 28:16.04.16.
  3. American Pharmacists Association. Venlafaxine, In: American Pharmacists Association. Drug Information Handbook: Lexi-Comp${\circledR}$, 2008; 1624-1627.
  4. Naranjo CA, Busto U, Sellers EM, et al., A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245. https://doi.org/10.1038/clpt.1981.154
  5. Leppert W, Majkowicz M. The impact of tramadol and dihydrocodeine treatment on quality of life of patients with cancer pain. Int J Clin Pract 2010; 64: 1681-1687. https://doi.org/10.1111/j.1742-1241.2010.02422.x
  6. Afshari R, Ghooshkhanehee H. Tramadol overdose induced seizure, dramatic rise of CPK and acute renal failure. J Pak Med Assoc 2009; 59: 178.
  7. Stamer UM, Stuber F, Muders T, et al., Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg 2008; 107: 926-929. https://doi.org/10.1213/ane.0b013e31817b796e
  8. Barnung SK, Treschow M, Borgbjerg FM. Respiratory depression following oral tramadol in a patient with impaired renal function. Pain 1997; 71: 111-112. https://doi.org/10.1016/S0304-3959(97)03350-2
  9. Pandey R, Elakkumanan LB, Garg R, et al., Prolonged apnea after small single dose of intravenous tramadol. AANA J 2010; 78: 110-112.
  10. Rollason V, Samer C, Piguet V, et al., Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics 2008; 9: 905-933. https://doi.org/10.2217/14622416.9.7.905
  11. Stamer UM, Lehnen K, Höthker F, et al., Impact of CYP2D6 genotype on ostoperative tramadol analgesia. Pain 2003; 105: 231-238. https://doi.org/10.1016/S0304-3959(03)00212-4
  12. Gholami K, Shalviri G, Zarbakhsh A, et al., New guideline for tramadol usage following adverse drug reactions reported to the Iranian Pharmacovigilance Center. Pharmacoepidemiol Drug Saf 2007; 16: 229-237. https://doi.org/10.1002/pds.1331